All In Biotech

Drug Trial Radar · NCT06455319

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil in Adolescents and Young Adults With Type 1 Diabetes

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 12, 2025

Primary completion

Nov 2028

Study completion Aug 2030

Sponsor

Lead sponsor
University of FloridaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Colorado, Denver; University of Miami
First posted
Jun 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

T cell directed therapy, anti-thymocyte globulin (ATG), in low doses, has been shown to lower HbA1c and preserve endogenous insulin production (measured by C-peptide) in individuals with recently diagnosed type 1 diabetes (T1D). However, not all individuals who received ATG responded to the therapy (i.e., non-responders). Additionally, use of ATG alone does not address inherent beta cell stress. A calcium channel blocker, verapamil, has demonstrated C-peptide preservation in newly diagnosed T1D. Investigators will identify those mostly likely to respond to ATG using an ex vivo predictive biomarker of response to ATG. In addition, Investigators will use sequential therapies to increase efficacy (ATG followed by verapamil) and explore synergistic mechanisms. This will be assessing with in depth immunophenotyping and quantify biomarkers of beta cell stress, cell death, and abnormal prohormone processing. Finally, novel clinical trial endpoints will be assessed for their ability to predict treatment efficacy earlier than the standard endpoint at 1 year.

Conditions

  • Type 1 Diabetes

Interventions

  • Anti-thymocyte globulin (ATG)Drug

    ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2).

  • verapamil extended release capsuleDrug

    Open label administration at 120, 240 or 360 mg daily based on weight and ECG findings

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC C-peptide between ATG responder and non-responder armsTime frame: 12 Months
  2. Change in 2-hr MMTT AUC C-peptideTime frame: 6 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Barbara Davis Center for Diabetes

    Aurora, Colorado · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.